CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE — CIRI

Centre International de Infectiologie

UNDERSTANDING INFECTIOUS DISEASES TO BETTER CONTROL THEM

http://ciri.ens-lyon.fr

RESEARCH TOPICS

- VIROLOGY
- BACTERIOLOGY
- IMMUNOLOGY
- EPIDEMIOLOGY AND ECO-INFECTIOLOGY

CROSS-CUTTING THEMES

LESSONS FROM THE DIVERSITY OF CLINICAL AND ENVIRONMENTAL STRAINS

 CELLULAR BIOLOGY OF
INFECTIONS AND INNATE IMMUNITY

 HIGHLY PATHOGENIC
VIRUSES IN HUMANS AND THEIR NATURAL RESERVOIRS

INFLAMMATORY DISEASES

IMMUNOTHERAPY
AND VACCINATION



RESEARCH EQUIPMENT AND TOOLS

- BioSafety Level 3 laboratories and main user of the BSL4 Jean Mérieux laboratory
- Shared platforms UAR Biosciences (PBES animal facility/AniRA, imaging/ cytometry, uectorology, etc.)
- EquipEx+ InfectioTron
- National Reference Centers: uiral hemorrhagic feuers, respiratory infections, staphylococci, legionella, etc.
- Study models: blood cells, mutant mice, humanized mouse

KEY FIGURES

| 420 | staff including 43 researchers, 83 professors and assitant professors including 58 medical professors and assistant professors, 17 hospital practitioners, 76 PhD students, 30 post-doctoral fellows and 130 research support staff |
|-----------------------------|--|
| Ouer 2015-2020: | |
| More than 600 | publications |
| 25 | prizes including: 1 Inserm Research Prize, 1 CNRS Bronze Medal, 2 Legions of Honor, 1 IUF |
| 28 | European funding (5 ERC as coordinator), 120 national funding type ANRt (60 as coordinator) |
| 68 | industrial contracts, 12 Cifre thesis, 3 public-private laboratories |
| 80 | intellectual properties: 27 patents filed, 13 licensed |
| TRL scale between 1 and 7-8 | |

CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE — CIRI



FOCUS ON

Institutional partnership research

The RHU IdBIORIV (Hospital-University Research) is a transdisciplinary partnership between CIRI (StaPath Team directed by F Vandenesch), the Institute of Analytical Sciences and the Canadian company SCIEX.

It was founded as part of the national Investments for the Future program (PIA).

> Objective: to develop – based on a proteomic approach – a sepsis diagnostic tool that can, in less than 60 minutes, identify the pathogen, characterize its antibiotic resistance profile and level of virulence.

Private partnership research

The start-up VAXXEL is working to develop a new intranasal pediatric vaccine.

Originating from the VirPath team, led by B Lina and M Rosa-Calatrava, this startup was rewarded during the i-Lab 2019 competition.

 > Objective: to develop a vaccine directed against human metapneumovirus (hMPV) and respiratory syncytial virus (RSV), responsible for bronchiolitis and pneumonia, especially in infants.

Find out more: https://uaxxel.fr

Collaboration between Boehringer Ingelheim and T Walzer LYACTS team

> **Objective:** to develop inhibitors of a molecule of the innate immune system, for the treatment of autoimmune and auto-inflammatory diseases.

FROM THE LABORATORY TO THE SOCIO-ECONOMIC WORLD

- Laboratory for basic and translational research in immunology and microbiology (bacteriology and uirology).
- Major player at the regional and/or national level in the diagnosis, prevention medicine and treatment of infectious and/or immune diseases.
- Strong roots in the local ecosystem interested in infectious diseases (HCL, VetAgroSup, Mérieux Foundation, Pasteur Institute, IRT BIOASTER, Lyonbiopôle, Sanofi, etc.)

CONTACT

CIRI – Inserm U1111, UMR 5308, Uniu Lyon 1 ENS de Lyon, Monod campus Director: François-Loïc Cosset Email: ciri@inserm.fr Telephone: +33 (0)4 37 28 23 60 http://ciri.ens-lyon.fr

🕆 Inserm







